Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy male and female adult volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

NCT03020498

Influenza

COMPLETED PHASE4

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974

Influenza

COMPLETED PHASE4

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

NCT02133781

Influenza

COMPLETED PHASE4

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

NCT00253734

Influenza

COMPLETED PHASE2

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

NCT03028987

Influenza

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to compare the response to different formulations of licensed influenza vaccines.

The type of seasonal influenza vaccination(s) received independently by volunteers in the year(s) since their last study visit will not impact eligibility. Volunteers will be assigned into one of three vaccine groups (intramuscular trivalent inactivated influenza vaccine (TIV); live attenuated influenza vaccine (LAIV- given year 1 only) or intradermal TIV, based on the type of study vaccine they received in 2010, 2011, 2012, or 2013. All participants will receive a single dose of their assigned seasonal influenza vaccine. Volunteers will complete 3 study visits at Day 0, Day 6-8 and Day 24-32.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A Fluzone® (IM)

Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)

2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study

Group Type EXPERIMENTAL

Fluzone® (IM)

Intervention Type BIOLOGICAL

This vaccine is given intramuscularly (IM)

Group B Fluzone® Intradermal (ID)

Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)

2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study

Group Type EXPERIMENTAL

Fluzone® Intradermal (ID)

Intervention Type BIOLOGICAL

This vaccine is given intradermally (ID)

Group C 2011-2012 FluMist®

Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.

FluMist was only used in the first year of study.

Group Type EXPERIMENTAL

2011-2012 FluMist®

Intervention Type BIOLOGICAL

This vaccine is given intranasally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluzone® (IM)

This vaccine is given intramuscularly (IM)

Intervention Type BIOLOGICAL

Fluzone® Intradermal (ID)

This vaccine is given intradermally (ID)

Intervention Type BIOLOGICAL

2011-2012 FluMist®

This vaccine is given intranasally

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Trivalent inactivated influenza vaccine (TIV) FDA-licensed seasonal influenza vaccine Trivalent inactivated influenza vaccine (TIV) FDA-licensed seasonal Influenza Vaccine Live, attenuated influenza vaccine (LAIV) FDA-licensed seasonal influenza vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Otherwise healthy, ambulatory between the ages of 8-33 years, inclusively.
* Willing to complete the informed consent process
* Availability for follow-up for the planned duration of the study at least 28 days after immunization
* Acceptable medical history and vital signs

Exclusion Criteria

* Prior vaccination with seasonal TIV or LAIV
* Prior off-study vaccination with TIV or LAIV in the current flu season
* Allergy to egg or egg products, or to vaccine components or thimerosal (TIV multidose vials only)
* Life-threatening reactions to previous influenza vaccinations
* Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
* Asthma or history of wheezing (for volunteers receiving LAIV only)
* Participants in close contact with anyone who has a severely weakened immune system should not receive LAIV (for volunteers receiving LAIV only)
* History of immunodeficiency (including HIV infection)
* Known or suspected impairment of immunologic function, including, but not limited to, clinically significant liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, or any other chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol
* Blood pressure \>150 systolic or \>95 diastolic at first study visit
* Chronic Hepatitis B or C
* Recent or current use of immunosuppressive medication, including systemic glucocorticoids (corticosteroid nasal sprays, inhaled steroids and topical steroids are permissible in both groups)
* Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia)
* Autoimmune disease (including rheumatoid arthritis) treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol
* History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
* Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except up to 325 mg. aspirin per day), Plavix, or Aggrenox must be reviewed by investigator to determine if this would affect the volunteer's safety
* Receipt of blood or blood products within the past 6 months or planned receipt of blood products prior to completion of study visits
* Medical or psychiatric condition or occupational responsibilities that preclude participant compliance with the protocol
* Inactivated vaccine 14 days prior to vaccination or planned non-study vaccination prior to completion of Visit 03 (\~Day 28 after the study vaccination)
* Live, attenuated vaccine within 60 days of vaccination or planned non-study vaccination prior to completion of Visit 03 (\~Day 28 after the study vaccination)
* Need an allergy immunization (that cannot be postponed) during the study period V01 to V03 (\~Day 28)
* History of Guillain-Barré Syndrome
* Pregnant or lactating woman
* Use of investigational agents within 30 days prior to enrollment or planned use of investigational agents prior to completion of study visits
* Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or planned blood donation prior to completion of study visits
* Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol

Minimum Eligible Age

8 Years

Maximum Eligible Age

34 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes